For advanced non-squamous non-small cell lung cancer, personalized neoantigen vaccines combined with chemotherapy and anti-programmed cell death protein 1 (PD-1) therapy have strong effects, especially on CD4 T cells[14]. The gene discussed is PDCD1; the disease is non-small cell squamous lung carcinoma.